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Vancomycin-resistant Enterococcus faecium (VREFM) is becoming a threatening pathogen. We iden-
tified a gene called DD1.5K by differential display-PCR, which was preferentially expressed in the
bloodstream isolates of VREFM. Due to its amino acid similarity to transfer complex protein, trsE, and
tissue-specific expression, this gene may be involved in virulence of VREFM. 
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in the United Kingdom (Uttley et al., 1988) and in France
(Leclercq et al., 1988) in 1988. Shortly after the first reports
were made, VRE were detected in hospitals in the United
States (Sahm et al., 1989). Since then, VRE have emerged
with unanticipated rapidity and, especially in the United
States, are now encountered in most hospitals (Martone,
1998). From the earliest reports of VRE clinical isolates,
most were VanA phenotype strains of E. faecium and were
associated with outbreaks in special units with immuno-
compromised patients on prolonged antimicrobial regi-
mens, with extended lengths of stay and higher severity-of-
illness scores (Sahm et al., 1989; Bonten et al., 1998).
Historically, the ratio of E. faecalis infections to those due
to all other Enterococcus species was approximately 10:1.
In recent years, there has been a progressive decline in this
ratio of enterococcal bacteremia (Shay et al., 1995). This
shift might be explained, in part, by the emergence of
E. faecium as a predominant species among enterococcal
isolates. Data from the National Nosocomial Infection Sur-
veillance (NNIS) survey evidences a rising percentage of
VRE since 1989, with rates now approaching 20% of all
enterococcal isolates (including all species); an equal pro-
portion of VRE isolates occurring in and out of intensive
care units; and E. faecium as the dominant species identi-
fied among VRE (although many enterococci are not iden-
tified) (CDC, 1993). In the countries of the European
Union (EU), VRE are relatively frequently found in healthy
humans in the community and in farm animals, and van-
comycin resistance is mostly vanA mediated. This consid-
erable pool of possibly transmissible isolates with vanA-
mediated glycopeptide resistance in the EU is very likely
caused by the use of avoparcin (an analogue of vancomy-
cin) as a growth promoter in animal husbandry until April
1997 (van den Bogaard et al., 1999; van den Bogaard et al.,
2000). Thus far, comprehensive studies have attempted to
identify the relationships between virulence and resistance
which enhance the organism's ability to cause disease
beyond those abilities commonly associated with entero-
cocci (Mundy et al., 2000).
In order to
 identify and isolate relevant genes of vanco-
mycin-resistant Enterococcus faecium (VREFM) whose
expressions are differentially induced during growth or
infection, we performed a comparative analysis of gene
expression pattern of the VREs isolated from different ori-
gins such as blood or urine by using differential display -
PCR (DD-PCR). 
The 75 vancomycin-resistant Enterococcus clinical iso-
lates were obtained from blood (n=27), rectal swab (n=19),
stool (n=9), urine (n=10), and from 10 chickens (rectal
swab). Single colony grown on Enterococcus selective
media (EnterococcoselTM agar, Becton Dickinson and Com-
pany, USA) was inoculated into 1ml of BHI broth and cul-
tured with shaking for 24 h at 37°C. The agar dilution
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(2002). Antimicrobial agents for minimal inhibitory con-
centration (MIC) were ampicillin, erythromycin, tetracy-
cline, levofloxacin, vancomycin, teicoplanin, gentamicin,
and streptomycin. Results were analyzed using the data-
base, APILIB+ (Bio-Merieux, France). Auxiliary experi-
ments (motility and pigment formation) for Enterococcus
species other than Enterococcus faecium and Enterococcus
faecalis were also performed.
DNA purification from standard strains and clinical iso-
lates was performed with the QIAamp DNA mini kit
(QIAGEN, Germany) in accordance with manufacturer's
instructions. RNA extraction was performed using the
RNeasy mini kit. A total of 1 to 5 µg of each sample was
subjected to RT-PCR or Northern (RNA) blot analysis. 
Differential display PCR was performed with the DeltaTM
Differential Display kit, in accordance with manufacturer's
instructions (Clontech, USA). The combination of forward
primers (F1 gacttctaatggggaaatttctaaa, F2 gacttctaatggaaaa-
atttctaaa) and reverse primers (R1 cgtatgatgaagcttccagttta,
R2 cgtatgatgaagcttccagggga) was determined based on the
alignment analysis of mRNAs from different Enterococcus
and other bacterial species. Briefly, Two microliter samples
containing 10 µg of total RNA with cDNA synthesis prim-
ers were incubated at 70oC for 3 min and then ice-cooled
for 2 min. Two microliters of cDNA synthesis buffer, con-
taining 100 mM Tris-HCl (pH 8.0), 100 mM KCl, 8 mM
MgCl2, 20 mM dithiothreitol, 5 mM deoxynucleoside tri-
phosphates, and 200 units of Moloney murine reverse trans-
criptase (Stratagene, USA), was added. The cDNA synthe-
sis was carried out at 42oC for 1 h and reactions were ter-
minated by incubating at 75oC for 10 min. After cDNA
synthesis, 2 µl of sample was subjected to DD-PCR with
the primer or in combination with other primers. The PCR
products were labeled with [α-33P]dATP (1,000-3,000 Ci/
mmol). The thermal cycling parameters were as follows:
94oC (5 min), 40oC (5 min), 68oC (5 min) for 1st cycle,
94oC (2 min), 40oC (5 min), 68oC (5 min) for 2 cycles, 94oC
(1min), 60oC (1 min), 68oC (2 min) for 25 cycles and
finally, 68oC (5 min) for the last. The RT-PCR samples
were analyzed by standard sequencing gels, and DD-PCR
fingerprints were autoradiographically visualized using
Kodak XAR film. Different RNA samples prepared from
VRE treated under co-culture with PBMC were finger-
printed, and duplicated signals from at least two DD-PCRs
were isolated and analyzed. In addition, in each reaction,
parallel experiments were carried out with negative and
positive control and, therefore, confirmed that the amplified
products were not due to DNA contamination. Differen-
tially expressed bands of DD-PCR products were cut from
the gel, and the DNA was eluted into 50 µl of TE by heat-
ing at 65oC for at least 1 h. Seven microliters of the eluent
Fig. 1. Identification of DD1.5K by DD-PCR and assignment of conceptual open reading frame (ORF) (GenBank accession no. AY273800)
a) Total RNA was purified from VREFM originating from rectal or blood samples and subjected to DD-PCR. The amplified products were resolved
on a denaturating polyacrylamide gel. The band representing DD1.5 K, which is preferentially expressed in the bloodstream isolate of VREFM, is
shown by an arrow. b) Using the partial sequence, full-length sequences were retrieved from the TIGR database and GenbankTM via bioinformatics.
The conceptual ORF was created by DNA Star software. 
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into the pGEM-T Easy vector (Promega, USA), and each
clone was sequenced with a model ABI Prism 310 genetic
analyzer (Perkin-Elmer, Applied Biosystems, USA). We
then analyzed the sequence data and performed homology
searches utilizing BLAST software and the GenBank data-
base. To confirm that the clones obtained, differentially
expressed genes derived from blood origin VRE, Northern
blot tests were performed. Probes obtained from RT-PCR
were labeled with [α-32P]dATP (Amersham Pharmacia
Biotech, USA) utilizing the PCR labeling method. The
PCR primer sequence was as follows: DD1.5K (291 bp),
sense, 5'-GTTTCACTTCCTCAAAC-TCG-3'; antisense,
5'-TTGTACCCCACGATCTAAAC-3'. Filters were hybrid-
ized overnight at 42oC with labeled probes. Washing of the
filters was performed at a final stringency of 0.1×SSC
(1×SSC is 0.15 M NaCl plus 0.015 M sodium citrate)-0.1%
sodium dodecyl sulfate (SDS) at 65oC. The blots were then
sealed in a plastic bag and subjected to autoradiography.
Clones containing cDNA from temperature-regulated
genes were sequenced using a T7-polymerase sequencing
kit (Pharmacia, UK). The nucleotide sequences obtained
were used to screen the GenBank and EMBL databases in
an attempt to identify the transcripts by using the BLASTN
and BLASTX programs, available at the National Center
for Biotechnology Information website.
All 27 blood stream isolates were resistant (MICs, 32 to
>128 µg/ml) to vancomycin as well as teicoplanin (MICs,
16 to >128 µg/ml). Of the 28 rectal or stool isolates (for
all of which the vancomycin MICs were 64 to >128 µg/
ml), only two were teicoplanin susceptible (MICs, 0.5 to
1µg/ml). All urine and chicken rectal isolates proved to be
highly resistant (MICs, 128 to >128 µg/ml) to vancomy-
cin while the range of teicoplanin resistance was high
overall in the chicken rectal isolates (MICs, 32 to
>128 µg/ml). Ampicillin resistance was seen in E.
faecium (MICs, 64 to >128 µg/ml), obtained from blood
and rectal swab, while susceptibility was demonstrated in
E. faecalis (MICs, 0.5 to 4 µg/ml). All the chicken rectal
isolates were susceptible to levofloxacin and the rest of
the clinical isolates were levofloxacin resistant (MICs, 8
to 128 µg/ml), ex-cepting 2 blood isolates (MICs, 2 µg/
ml), which were levofloxacin susceptible.
As seen in Fig. 1a, a specific gene fragment was iden-
tified by DD-PCR from total RNA from the bloodstream
VREFM, which was named DD1.5 k (GenBank acces-
sion no. AY273800). From data obtained from the dot blot
analysis, we did not see any gene expressions in other
major Enterococcus species, such as vancomycin-resistant
E. faecalis and major gram-negative organisms. Utilizing
the TIGR bacterial genome database, we retrieved a full
length DNA and a conceptual open reading frame (ORF)
was constructed by DNA Star software. Genbank
searches revealed
 no significant homology to any known
sequence. However, the translated amino acid sequences
(as shown in Fig. 1b) of this gene showed a limited
homology to transfer complex protein trsE, a hypothetical
ORF of Bacillus anthracis plasmid pX02 (34%) and an
ORF of Clostridium perfringens plasmid pCP13 DNA
(31%) (Table 1). 
Fig. 2 shows a representative RT-PCR data reflecting
preferential expressions of DD1.5k in the bloodstream
isolates of VREFM. DD1.5k RNA are fairly abundant
(65%, 18 out of 27) in the VREFM derived from blood
compared to that from rectal, stool (15%, 4 out of 28), or
other isolates from urine (10%, 1 out of 10) and chicken
rectal isolates (0%, 0 out of 10). 
This data strongly suggests that the expression of
DD1.5 k is associated with onset of bacteremia caused by
VREFM. It also indicates that the horizontal transfer of
this gene, between species such as chicken and human,
has not occurred. According to Rice et al. (2003), The
presence of espefm was roughly twice that of the newly
cloned gene, hylefm, but both were found primarily in
VREFM isolates in non-stool cultures obtained from
patients hospitalized in the United States. His data showed
that even though variations exist, specific E. faecium
strains exhibit these virulent genotypes and these genes
might cause more serious clinical infections. In our study,
similar results have been observed. We believe that the
Table 1. Sequence homology analysis of translated amino acid of DD1.5K (GenBank accession no. AY273800)
Accession no. Total Predicted protein Similar portion ofPredicted protein




AF188935.1 Bacillus anthracis plasmid pXO2 similar to transfer complex protein trsE 108/310 (34%) 202
AE011191.1 Bacillus anthracis str. A2012 plasmid pXO2 conserved hypothetical protein 108/310 (34%) 202
AP003515.1 Clostridium perfringens plasmid Pcp13 conserved hypothetical protein 098/312 (31%) 157
Fig. 2. Preferential expression of DD1.5K in the bloodstream isolate of
VREFM: Total RNA was isolated from VREFM from blood or rectal
samples. DD1.5 K was detected by RT-PCR. 16S RNA was amplified
also, as a control. The resulting products were separated by agarose gel
electrophoresis. The marks mentioned were serial numbers of clinical
isolates.
146 Kim et al. J. Microbiol.expression of DD1.5K genes cloned from blood-derived
E. faecium might be closely related to virulence. The rea-
son is that bacteremic patients infected by blood-derived
VREFM eventually died, whereas those infected by stool,
rectal, and urine-derived VREFM did not. Furthermore,
VREFM, other than blood-derived strains, did not cause
any significant symptoms or signs of infection. In sum-
mary, for mass surveillance purposes, we postulate that
the detection of DD1.5K - E. faecium, not only in blood
but also from various origins - might play an important
role in predicting bacteremic virulence. Furthermore, it is
possible that DD1.5k could be used as a marker for diag-
nostic or prognostic purpose, for bacteremia caused by
VREFM. 
To our knowledge, this is the first experimental
 evidence
that a specific gene is differentially regulated
 by blood-
stream isolates of VREFM.
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